Intellectual Property

miReven holds worldwide exclusive rights to the UWA miR-7 patents, creating a solid IP portfolio protecting the commercialisation of miR-7 as an anti-cancer therapeutic.
Our patent estate includes 4 patent families to date, 3 of which are published and have entered National Phase examination in multiple jurisdictions including the US and Europe.

 

Title Publication Details Type Inventors
1 Method of Modulation of Expression of Epidermal Growth Factor Receptor (EGF-R) involving miRNA US 8673872-Granted

EP 2061482 - Granted

Method of use miR-7 cancer (EGFR-related) Peter Leedman

Keith Giles

Rebecca Webster

2 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors AU 2010324530 - Granted

CA 2781572 - Pending

US 9051551- Granted

EU 2521555 - Granted

Methods and composition for miR-7 combination therapy Peter Leedman

Keith Giles

Felicity Kalinowski

3 Cancer therapy using miRNAs US 9795626 - Granted

EU 13847499.4 – under examination

IN 4209/DELNP/2015 - pending

CH 201380065503.0 - pending

Methods of use miR-7 cancer (IGFR-related, melanoma) Peter Leedman

Keith Giles

Rikki Brown